The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine

Canadian Journal of Ophthalmology

Volumn 46, Issue 3, 2011, Pages 289-290

  Mulholland, Conor P ^a   Pollock, Travis J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE;

CASE REPORT; CORNEA OPACITY; CORNEA THICKNESS; DISEASE SEVERITY; ECHOGRAPHY; EYE FIXATION; FEMALE; HUMAN; INFANT; LENS; LETTER; MATERNAL DISEASE; PETERS ANOMALY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; RHEUMATOID ARTHRITIS; TELANGIECTASIA; TREATMENT DURATION;

EID: 84455190176     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2011.05.001     Document Type: Letter

References (7)

1. Harissi-Dagher M, Colby K. Anterior segment dysgenesis: Peters' anomaly and sclerocornea. Int Ophthalmol Clin. 2008;48:35-42. (Pubitemid 351572187)
2. Lloyd M, Carr M, McElhatton P, et al. The Effects of methotrexate on pregnancy, fertility and lactation. Q J Med. 1999;92:551-63. (Pubitemid 29501961)
3. Armstrong C, Monie IW. Congenital eye defects in rats following maternal folic-acid deficiency during pregnancy. J Embryol Exp Morphol. 1966:16:532-42.
4. Nelson, MM. Production of congenital anomalies in mammals by maternal dietary deficiencies. Pediatrics. 1957;19:764-75.
5. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheum. 2003;48:3207-11.
6. Charlap JH, Donahue RJ, Knudsen TB. Exposure-disease continuum for 2-chloro-2′-deoxyadenosine, a teratogen. Birth Defects Res. 2003;67:108-15.
7. Chan T, Bowell R, O'Keefe M, Lanigan B. Ocular manifestations in fetal alcohol syndrome. Br J Ophthalmol. 1991;75:524-26.